680 related articles for article (PubMed ID: 31678210)
1. Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy.
Abdel-Wahab AF; Mahmoud W; Al-Harizy RM
Pharmacol Res; 2019 Dec; 150():104511. PubMed ID: 31678210
[TBL] [Abstract][Full Text] [Related]
2. Anticancer strategies based on the metabolic profile of tumor cells: therapeutic targeting of the Warburg effect.
Chen XS; Li LY; Guan YD; Yang JM; Cheng Y
Acta Pharmacol Sin; 2016 Aug; 37(8):1013-9. PubMed ID: 27374491
[TBL] [Abstract][Full Text] [Related]
3. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression.
Vaupel P; Schmidberger H; Mayer A
Int J Radiat Biol; 2019 Jul; 95(7):912-919. PubMed ID: 30822194
[TBL] [Abstract][Full Text] [Related]
4. p53 and glucose metabolism: an orchestra to be directed in cancer therapy.
Gomes AS; Ramos H; Soares J; Saraiva L
Pharmacol Res; 2018 May; 131():75-86. PubMed ID: 29580896
[TBL] [Abstract][Full Text] [Related]
5. UP12, a novel ursolic acid derivative with potential for targeting multiple signaling pathways in hepatocellular carcinoma.
Dong H; Yang X; Xie J; Xiang L; Li Y; Ou M; Chi T; Liu Z; Yu S; Gao Y; Chen J; Shao J; Jia L
Biochem Pharmacol; 2015 Jan; 93(2):151-62. PubMed ID: 25522955
[TBL] [Abstract][Full Text] [Related]
6. Modulating autophagy in cancer therapy: Advancements and challenges for cancer cell death sensitization.
Bhat P; Kriel J; Shubha Priya B; Basappa ; Shivananju NS; Loos B
Biochem Pharmacol; 2018 Jan; 147():170-182. PubMed ID: 29203368
[TBL] [Abstract][Full Text] [Related]
7. Metabolic reprogramming by traditional Chinese medicine and its role in effective cancer therapy.
Wang S; Fu JL; Hao HF; Jiao YN; Li PP; Han SY
Pharmacol Res; 2021 Aug; 170():105728. PubMed ID: 34119622
[TBL] [Abstract][Full Text] [Related]
8. Revisiting the Warburg effect: historical dogma versus current understanding.
Vaupel P; Multhoff G
J Physiol; 2021 Mar; 599(6):1745-1757. PubMed ID: 33347611
[TBL] [Abstract][Full Text] [Related]
9. Tumor glycolysis as a target for cancer therapy: progress and prospects.
Ganapathy-Kanniappan S; Geschwind JF
Mol Cancer; 2013 Dec; 12():152. PubMed ID: 24298908
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of glycolysis in cancers and therapeutic opportunities.
Warmoes MO; Locasale JW
Biochem Pharmacol; 2014 Nov; 92(1):12-21. PubMed ID: 25093285
[TBL] [Abstract][Full Text] [Related]
11. Anticancer agents that counteract tumor glycolysis.
Granchi C; Minutolo F
ChemMedChem; 2012 Aug; 7(8):1318-50. PubMed ID: 22684868
[TBL] [Abstract][Full Text] [Related]
12. The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies.
El Hassouni B; Granchi C; Vallés-Martí A; Supadmanaba IGP; Bononi G; Tuccinardi T; Funel N; Jimenez CR; Peters GJ; Giovannetti E; Minutolo F
Semin Cancer Biol; 2020 Feb; 60():238-248. PubMed ID: 31445217
[TBL] [Abstract][Full Text] [Related]
13. The sweet trap in tumors: aerobic glycolysis and potential targets for therapy.
Yu L; Chen X; Wang L; Chen S
Oncotarget; 2016 Jun; 7(25):38908-38926. PubMed ID: 26918353
[TBL] [Abstract][Full Text] [Related]
14. Sirtuin 1 in osteoarthritis: Perspectives on regulating glucose metabolism.
Liao Z; Cai X; Zheng Y; Lin J; Yang X; Lin W; Zhang Y; He X; Liu C
Pharmacol Res; 2024 Apr; 202():107141. PubMed ID: 38490314
[TBL] [Abstract][Full Text] [Related]
15. The determinants of metabolic discrepancies in aerobic glycolysis: Providing potential targets for breast cancer treatment.
Littleflower AB; Parambil ST; Antony GR; Subhadradevi L
Biochimie; 2024 May; 220():107-121. PubMed ID: 38184121
[TBL] [Abstract][Full Text] [Related]
16. Targeting the Warburg effect for cancer treatment: Ketogenic diets for management of glioma.
Poff A; Koutnik AP; Egan KM; Sahebjam S; D'Agostino D; Kumar NB
Semin Cancer Biol; 2019 Jun; 56():135-148. PubMed ID: 29294371
[TBL] [Abstract][Full Text] [Related]
17. Targeting antioxidants for cancer therapy.
Glasauer A; Chandel NS
Biochem Pharmacol; 2014 Nov; 92(1):90-101. PubMed ID: 25078786
[TBL] [Abstract][Full Text] [Related]
18. Selective anti-tumor activity of wogonin targeting the Warburg effect through stablizing p53.
Zhao Y; Zhang L; Wu Y; Dai Q; Zhou Y; Li Z; Yang L; Guo Q; Lu N
Pharmacol Res; 2018 Sep; 135():49-59. PubMed ID: 30031170
[TBL] [Abstract][Full Text] [Related]
19. Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways.
Lernoux M; Schnekenburger M; Dicato M; Diederich M
Pharmacol Res; 2018 Mar; 129():337-356. PubMed ID: 29133216
[TBL] [Abstract][Full Text] [Related]
20. Metabolic effects of antiangiogenic drugs in tumors: therapeutic implications.
Quintieri L; Selmy M; Indraccolo S
Biochem Pharmacol; 2014 May; 89(2):162-70. PubMed ID: 24607274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
